Zhejiang Siwei Pharmaceutical Technology

Zhejiang Siwei Pharmaceutical Technology is a clinical-stage biotechnology company based in Hangzhou, China, dedicated to the discovery and development of innovative small molecule therapeutics. The company focuses on high-impact therapeutic areas including metabolic diseases, oncology, and inflammatory disorders, utilizing a proprietary drug design and medicinal chemistry platform. Its lead candidate, SW-0442, is a potent and selective SGLT2 inhibitor currently in Phase 2 clinical trials for the treatment of type 2 diabetes. In addition to its internal R&D pipeline, Zhejiang Siwei operates as a CRO and CDMO, providing high-end chemical synthesis and process optimization services to the global pharmaceutical industry. The company is supported by leading venture capital investors and maintains state-of-the-art research and development facilities.